A Phase 1 interventional study of 26-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Diseases, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.
Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 14th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 14th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States, Argentina and 8 more countries
Ages 42 days–98 days · Healthy volunteers
GPN Vaccines · Sites in Australia
Ages 18–69 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 12
First in 2006; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 60 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 851 across the 16 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 16 have an industry lead sponsor. The 6 most frequent:
This study is registered under Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, one of the names counted as Chongqing Zhifei Biological Products Co., Ltd.. Under that name alone:
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd is the lead sponsor of 22 studies on the registry; 5 are open to participants now.
Chongqing Zhifei Biological Products Co., Ltd. has 2 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Pneumococcal Infections with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either 26-valent Pneumococcal Conjugate Vaccine (PCV26) or the comparator (PCV13) on Day 1 (Visit 1). Solicited adverse events (AEs) will be collected for 7 days post-vaccination and unsolicited AEs for 28 days post-vaccination, with safety data limited to serious adverse events (SAEs), and newly diagnosed chronic medical conditions (NDCMCs) collected up to 6 months post-vaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 subjects aged ≥60 are enrolled in this group.
Biological: 26-valent Pneumococcal Conjugate Vaccine
30 subjects aged ≥ 60 years are enrolled in this group.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Subjects were treated with a single intramuscular injection of 26-valent Pneumococcal Conjugate Vaccine.
Subjects were treated with a single intramuscular injection of 13-valent Pneumococcal Conjugate Vaccine.
Solicited AEs within 0-7 days after vaccination
The frequencies and percentages of participants reporting solicited AEs in injection within 7 days after vaccination in each group
Time frame: Within 0-7 days after vaccination.
Solicited systemic AEs within 0-7 days after vaccination
The frequencies and percentages of participants reporting solicited systemic AEs within 7 days after vaccination in each group.
Time frame: Within 0-7 days after vaccination.
Unsolicited AEs within 0-28 days after vaccination
The frequencies and percentages of participants reporting unsolicited AEs within 0-28 days after vaccination in each group.
Time frame: Within 0-28 days after vaccination.
SAEs and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination
The frequencies and percentages of participants reporting SAEs and NDCMCs within 6 months after vaccination.
Time frame: Within 0-6 months after vaccination.
Laboratory testing clinically abnormalities on the 7th day after vaccination
The frequencies and percentages of participants with laboratory testing clinically abnormalities on the 7th day after vaccination in each group.
Time frame: On the 7th day after vaccination
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for Nov 2025, 6 months later.
Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd →